Recombinant Advantage Aviva Systems Biology is well positioned to win with its strength in recombinant antibodies, antibody discovery, and assay development aimed at diagnostic workflows. Target biotech, pharma, and translational research teams seeking robust biomarker assays and reliable reagents across neuroscience, cancer, and immunology.

Product Expansion Recent launches of anti-progranulin recombinant monoclonal antibody clones and the AvivaBlot ECL reagents broaden the addressable need for neurodegenerative targets and Western blot workflows. These products create cross-sell opportunities for semi-custom proteins, assay components, and validated reagents across research and preclinical programs.

Global Reach A global distributor network enables rapid market penetration and regional support for Aviva’s antibodies, proteins, and assay kits. Leverage partners for localized marketing, technical training, and field enablement to accelerate adoption in new geographies and mid-size laboratories.

Targeted Verticals A focused portfolio aimed at neuroscience, cancer, and immunology researchers aligns with high-value translational work and neurodegenerative disease programs such as progranulin studies. Build vertical solutions, biomarker panels, and ready-to-use assay templates tailored to these segments.

Collaboration Potential Existing and potential partnerships in semi-custom proteins, sample preparation, and diagnostic workflows indicate strong collaboration opportunities with CROs, academic consortia, and industry partners. Position Aviva as a co-development partner for assays, reagents, and diagnostic-ready solutions.